Note to visitors looking for an update on Aimspro's Optic Neuritis trials (as of March 21, 2005): We are covering that story on the front page, click here to see it.
A promising update from Daval, makers of Aimspro (better known as "the goat serum", formerly known as "Caprivax").
"Daval’s mission is to make 'Aimspro' available to all those who wish to take advantage of its therapeutic properties, as quickly as possible...
To attain this goal we need to achieve certain clinical, regulatory and commercial objectives which I am confident we are on course to do...
As so many friends of Daval are aware, Aimspro is particularly suited to the treatment of neural disorders, such as multiple sclerosis, although we are becoming increasingly impressed with its applicability to other disorders of an inflammatory nature. The 150 patients who are already receiving Aimspro on an informed consent basis all attest to its efficacy. Daval is confident that those receiving it on the authorised trials currently taking place in this country will provide a similar endorsement in due course..."
Looking good! Click "read more" for the full update...
Advertisement
Full Article Text
Daval’s mission is to make "Aimspro'" available to all those who wish to take advantage of its therapeutic properties, as quickly as possible.
To attain this goal we need to achieve certain clinical, regulatory and commercial objectives which I am confident we are on course to do. The first is in our own hands and those of our eminent team of scientists. Increasing vocal patient demand will add weight to our regulatory submissions, and a projected partnership with a larger marketing organisation will assist in attaining the third objective.
As so many friends of Daval are aware, Aimspro is particularly suited to the treatment of neural disorders, such as multiple sclerosis, although we are becoming increasingly impressed with its applicability to other disorders of an inflammatory nature. The 150 patients who are already receiving Aimspro on an informed consent basis all attest to its efficacy. Daval is confident that those receiving it on the authorised trials currently taking place in this country will provide a similar endorsement in due course. We are keeping the appropriate government departments regularly apprised of the development of our remarkable medication in anticipation that they will help Daval to fast track its general availability.
We feel it would certainly be in their interest to do so as we are already achieving significant savings for the National Health Service by freely treating patients. When the product's true potential is fully realised these savings would amount to many, many millions of pounds. This would also be consistent with the Government’s frequently stated intention of strongly supporting the British bio-technology industry.
Daval has a growing number of supporters who are assisting its progress with their varied skills and the Board is most grateful for their continuing encouragement during this crucial development period.”
Brian Quick. July 2004
Source: http://www.davalinternational.com/markup/about.cfm
Note: Thank you to our member "Nemotoday" who pointed this article out to us.
